Figure 1. DOAC use in renal insufficiency.

*Apixaban dose adjustments are based on patient serum creatinine, age, and body weight; **rivaroxaban dose adjustments are based on patient indication; ***betrixaban: no dose adjustments provided for hemodialysis patients (has not been studied). CrCl indicates Cockcroft‐Gault creatinine clearance; ESRD, end‐stage renal disease; NVAF, nonvalvular atrial fibrillation; and VTE, venous thromboembolism.